174 related articles for article (PubMed ID: 19554396)
21. Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease.
Nishioka H; Takegawa H; Kamei H
J Infect Chemother; 2018 Feb; 24(2):138-141. PubMed ID: 29021093
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
[TBL] [Abstract][Full Text] [Related]
23. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
24. [Effectiveness of long term administration of humanized anti-interleukin-6 receptor antibody (tocilizumab) for multicentric Castleman's disease with pulmonary involvement].
Akahane D; Kimura Y; Sumi M; Sashida G; Gotoh A; Miyazawa K; Ohyashiki K
Rinsho Ketsueki; 2006 Aug; 47(8):748-52. PubMed ID: 16986713
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan.
Murakami M; Johkoh T; Hayashi S; Ohshima S; Mizuki M; Nakatsuka SI; Tomobe M; Kuroyanagi K; Nakasone A; Nishimoto N
Mod Rheumatol; 2020 Sep; 30(5):843-851. PubMed ID: 31829070
[No Abstract] [Full Text] [Related]
27. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
Sugawara E; Sato T; Amasaki Y; Katsumata K
Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301
[TBL] [Abstract][Full Text] [Related]
28. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
Lee JP; Kim DK; Oh DY; Paik JH; Moon KC; Kim S; Kim YS
Clin Nephrol; 2011 Feb; 75(2):165-70. PubMed ID: 21255547
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
Nishi J; Maruyama I
Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
[TBL] [Abstract][Full Text] [Related]
30. Comparison of IgG4-Related Lymphadenopathy and Multicentric Castleman's Disease: a Retrospective Study.
Sun C; Xu G; Lin J
Clin Lab; 2018 Oct; 64(10):1671-1678. PubMed ID: 30336525
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
Song SN; Tomosugi N; Kawabata H; Ishikawa T; Nishikawa T; Yoshizaki K
Blood; 2010 Nov; 116(18):3627-34. PubMed ID: 20644113
[TBL] [Abstract][Full Text] [Related]
33. Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease.
Man L; Goudar RK
Eur J Haematol; 2013 Sep; 91(3):273-276. PubMed ID: 23786462
[TBL] [Abstract][Full Text] [Related]
34. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
Nagao A; Nakazawa S; Hanabusa H
J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
[TBL] [Abstract][Full Text] [Related]
35. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.
Newsom-Davis T; Bower M; Wildfire A; Thirlwell C; Nelson M; Gazzard B; Stebbing J
Leuk Lymphoma; 2004 Sep; 45(9):1939-41. PubMed ID: 15223659
[TBL] [Abstract][Full Text] [Related]
36. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease.
Ebisawa K; Shimura A; Honda A; Masamoto Y; Nakahara F; Kurokawa M
Leuk Lymphoma; 2021 Mar; 62(3):614-619. PubMed ID: 33076723
[TBL] [Abstract][Full Text] [Related]
37. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
Ohsugi Y; Tsuchimoto N
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
[No Abstract] [Full Text] [Related]
39. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
Nishi J; Arimura K; Utsunomiya A; Yonezawa S; Kawakami K; Maeno N; Ijichi O; Ikarimoto N; Nakata M; Kitajima I; Fukushige T; Takamatsu H; Miyata K; Maruyama I
Br J Haematol; 1999 Mar; 104(3):482-5. PubMed ID: 10086783
[TBL] [Abstract][Full Text] [Related]
40. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
